Clinical Takeaway
In this phase 3 randomized controlled trial of 820 adults with chronic low back pain, VER-01, a full-spectrum cannabis extract, was evaluated over a 12-week blinded treatment period with extended follow-up lasting up to one year. The trial design included both open-label extension and randomized withdrawal phases, allowing for assessment of sustained efficacy and safety. Results from this rigorously structured study add meaningful clinical evidence regarding cannabis-based treatment options for a condition where current pharmacologic therapies remain inadequate.
#1 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a significant clinical gap by providing rigorous evidence for cannabis-derived therapeutics in chronic low back pain, a condition affecting over 500 million people globally where current pharmacologic options demonstrate limited efficacy and notable adverse effect profiles. The large sample size (820 participants) and double-blind design with extended follow-up strengthen the reliability of safety and efficacy data, enabling evidence-based clinical decision-making regarding full-spectrum cannabis extracts as an alternative treatment modality. If efficacious and well-tolerated, VER-01 could offer clinicians a potentially safer analgesic option for patients with chronic low back pain who have exhausted or cannot tolerate conventional therapies.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
💊 This phase 3 trial adds meaningful data to the cannabis-for-pain literature by demonstrating efficacy of a full-spectrum extract in chronic low back pain, a condition where traditional pharmacotherapy often falls short. However, clinicians should note several important considerations before integrating these findings into practice: the study’s generalizability may be limited by its specific cultivar and extraction method, patient selection bias is common in cannabis trials, and we lack clarity on whether benefits persist beyond the study duration or in real-world polypharmacy contexts with other pain medications. Additionally, the full abstract does not detail safety outcomes, cannabinoid concentrations, or how results compare to established non-pharmacologic interventions like physical therapy, which remain first-line for many CLBP patients. Given this evidence, VER-01 may be a reasonable consideration for patients with inadequate response to or intolerance of conventional treatments, though individual dosing, drug interactions, and realistic outcome expectations should be discussed candidly, and patients should continue evidence-based rehabilitation